At the 2024 Society of Neuro-Oncology (SNO) Annual Meeting held in Texas, USA, J INTS BIO revealed its research findings on a cutting-edge brain tumor therapy named ‘JIN-001,’ developed jointly with MD Anderson Cancer Center.
Partnered since 2021, MD Anderson, a world-leading cancer research facility, has been collaborating with J INTS BIO to advance this innovative treatment.
The ‘JIN-001’ solution targets glioblastoma (GBM) cells by significantly improving the effectiveness of radiation and chemotherapy treatments. By acting as a selective inhibitor of HSP90 (Heat Shock Protein 90), its significant benefit is its capacity to traverse the blood-brain barrier (BBB). Typically, the BBB serves as a safeguard for the brain but also poses a hindrance for drug delivery. JIN-001 resolves this challenge by penetrating the barrier and targeting brain tumors directly, overcoming the previous difficulties faced by medications due to the BBB’s low permeability.
The findings also underscored JIN-001’s promising capacity to work in combination with standard treatments like Radiation Therapy and Temozolomide, resulting in successful suppression of tumor cell proliferation and initiation of apoptosis (programmed cell death).
Encouraged by promising outcomes, J INTS BIO plans to expedite preclinical trials for JIN-001. The company aims to incorporate CRISPR gene-editing technology in assessing the impact of certain genetic elements in treatment resistance, fostering precision medicine techniques. CRISPR technology allows for precise modulation of gene expression, aiding predictions and enhancing understanding of tumor behaviors.
Further, J INTS BIO is also moving forward with efforts to commercialize JIN-001 by teaming up with international pharmaceutical enterprises, aspiring to provide more rapid and efficient treatments to individuals battling brain tumors. Additionally, the treatment’s potential applications in combating various cancer types beyond brain tumors are being examined, offering renewed hope to patients globally.
JIN-001 emerges as a visionary therapy that eliminates the barriers faced by current treatments, offering new avenues for therapy and hope for superior survival and quality of life for those afflicted with brain tumors.